Abstract
Gene therapy offers several novel advantages to the treatment of arthritis and other joint diseases. Therapeutic genes may be delivered locally to diseased joints or systemically to extra-articular locations using viral or non-viral vectors by ex vivo or in vivo strategies. Pre-clinical experiments with rabbits have demonstrated the utility of using a retrovirus to deliver the human interleukin-1 receptor antagonist to the synovial lining of joints. A human trial based on this principle has been approved by the Recombinant DNA Advisory Committee of NIH and should begin this year.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 543-546 |
| Number of pages | 4 |
| Journal | Annals of Medicine |
| Volume | 27 |
| Issue number | 5 |
| DOIs | |
| State | Published - 1995 |
| Externally published | Yes |
Bibliographical note
Funding Information:The authors’ work is this area is supported by NIH grant PO1 DK44935, Theragen Inc. and Orthogen GmbH. We thank Mrs Lou Duerring for typing the manuscript.
Keywords
- Arthritis
- Gene therapy
- Interleukin-1 receptor antagonist
- Synovium
Fingerprint
Dive into the research topics of 'Progress toward the treatment of arthritis by gene therapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS